CNS Drugs

, Volume 22, Issue 1, pp 15–26 | Cite as

Neurobiological and Clinical Effects of the Antidepressant Tianeptine

  • Siegfried KasperEmail author
  • Bruce S. McEwen
Review Article


The precise neurobiological processes involved in depression are not clear, but it is recognized that numerous factors are involved, including changes in neurotransmitter systems and brain plasticity. Neuroplasticity refers to the ability of the brain to adapt functionally and structurally to stimuli. Impairment of neuroplasticity in the hippocampus, amygdala and cortex is hypothesized to be the mechanism by which cognitive function, learning, memory and emotions are altered in depression. The mechanisms underlying alterations in neuroplasticity are believed to relate to changes in neurotransmitters, hormones and growth factors. Structural changes in the hippocampus that have been proposed to be associated with depression include dendritic atrophy, reduced levels of cerebral metabolites, decreased adult neurogenesis (generation of new nerve cells) and reduced volume. Increased dendritic branching occurs in the basolateral nucleus of the amygdala. Reduced neuronal size and glial cell density occur in the prefrontal cortex.

Clinically, tianeptine is an antidepressant effective in reducing symptoms of depression in mild to moderate-to-severe major depression, including over the long term. Tianeptine is also effective in alleviating the symptoms of depression-associated anxiety. It is generally well tolerated, with little sedation or cognitive impairment.

The efficacy profile of tianeptine could be explained by its neurobiological properties observed in animal models. Tianeptine prevents or reverses stress-associated structural and cellular changes in the brain and normalizes disrupted glutamatergic neurotransmission. In particular, in the hippocampus, it prevents stress-induced dendritic atrophy, improves neurogenesis, reduces apoptosis and normalizes metabolite levels and hippocampal volume. Tianeptine also has beneficial effects in the amygdala and cortex and can reverse the effects of stress on neuronal and synaptic functioning.

The neurobiological properties of tianeptine may provide an explanation not only for its antidepressant activity, but also for its anxiolytic effects in depressed patients and its lack of adverse effects on cognitive function and memory.


Fluoxetine Paroxetine Sexual Dysfunction Hippocampal Volume Tianeptine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Medical writing support was provided by Tracy Harrison and Mary Hines from Wolters Kluwer Health Medical Communications. This assistance was funded by Laboratoires Servier. The authors have been actively involved in the construction of the paper from the outset and have had full editorial control over its content.

Dr Kasper has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Servier, Sepracor, Janssen, and Novartis; and has served on speakers’ bureaus for AstraZeneca, Eli Lilly, Lundbeck, Sepracor, Servier and Janssen. Dr McEwen has received honoraria from Servier for lectures and articles concerning basic research on tianeptine, including this article.


  1. 1.
    National clinical practice guideline number 23. Depression: management of depression in primary and secondary care, 2004 [online]. Available from URL: [Accessed 2007 Jul 31]
  2. 2.
    McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005 Jun; 10(6): 525–37PubMedCrossRefGoogle Scholar
  3. 3.
    Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61Suppl. 6: 4–6PubMedGoogle Scholar
  4. 4.
    Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. ScientificWorldJournal 2006; 6: 53–80PubMedCrossRefGoogle Scholar
  5. 5.
    Duman RS. Neural plasticity: consequences of stress and actions of antidepressant treatment. Dialog Clin Neurosci 2004; 6(2): 157–69Google Scholar
  6. 6.
    Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. Epub 2007 May 14Google Scholar
  7. 7.
    Pillai AG, Munoz C, Chattarji S. The antidepressant tianeptine prevents the dendritic hypertrophy in the amygdala and increase in anxiety induced by chronic stress in the rat [abstract no. 762.1]. 34th Annual Meeting of the Society for Neuroscience; 2004 Oct 21–22; San Diego (CA)Google Scholar
  8. 8.
    McEwen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann N Y Acad Sci 1997; 821: 271–84PubMedCrossRefGoogle Scholar
  9. 9.
    McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur Neuropsychopharmacol 2004 Dec; 14Suppl. 5: S497–502PubMedCrossRefGoogle Scholar
  10. 10.
    Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001 Oct 23; 98(22): 12796–801PubMedCrossRefGoogle Scholar
  11. 11.
    Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci 1995 Jun; 15(6): 4687–92PubMedGoogle Scholar
  12. 12.
    Vouimba RM, Munoz C, Diamond DM. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. Stress 2006 Mar; 9(1): 29–40PubMedCrossRefGoogle Scholar
  13. 13.
    Bremner JD, Vythilingam M, Vermetten E, et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002 Feb 15; 5 1(4): 273–9CrossRefGoogle Scholar
  14. 14.
    Drevets WC, Price JL, Simpson Jr JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997 Apr 24; (6627) 824–7CrossRefGoogle Scholar
  15. 15.
    Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000 Jan; 157(1): 115–8PubMedGoogle Scholar
  16. 16.
    Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002 Jul; 159(7): 1112–8PubMedCrossRefGoogle Scholar
  17. 17.
    Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003 Aug; 160(8): 1516–8PubMedCrossRefGoogle Scholar
  18. 18.
    Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999 Jun 15; 19(12): 5034–43PubMedGoogle Scholar
  19. 19.
    Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998 Jun 22; 9(9): 2023–8PubMedCrossRefGoogle Scholar
  20. 20.
    Frodl T, Meisenzahl E, Zetzsche T, et al. Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry 2002 May 1; 51(9): 708–14PubMedCrossRefGoogle Scholar
  21. 21.
    Herrmann MJ, Ehlis AC, Fallgatter AJ. Bilaterally reduced frontal activation during a verbal fluency task in depressed patients as measured by near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci 2004 Spring; 16(2): 170–5PubMedCrossRefGoogle Scholar
  22. 22.
    Cotter D, Mackay D, Landau S, et al. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001 Jun; 58(6): 545–53PubMedCrossRefGoogle Scholar
  23. 23.
    Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999 May 1; 45(9): 1085–98PubMedCrossRefGoogle Scholar
  24. 24.
    Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998 Oct 27; 95(22): 13290–5PubMedCrossRefGoogle Scholar
  25. 25.
    Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004 Mar 15; 55(6): 563–9PubMedCrossRefGoogle Scholar
  26. 26.
    Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006 Jun 15; 59(12): 1116–27PubMedCrossRefGoogle Scholar
  27. 27.
    Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999 Apr 29; 371(2-3): 113–22PubMedCrossRefGoogle Scholar
  28. 28.
    Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000; 126: 413–31PubMedCrossRefGoogle Scholar
  29. 29.
    Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000 Oct 15; 48(8): 813–29PubMedCrossRefGoogle Scholar
  30. 30.
    Drevets WC, Price JL, Bardgett ME, et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 2002 Mar; 71(3): 431–47PubMedCrossRefGoogle Scholar
  31. 31.
    Agid Y, Buzsaki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discover 2007 Mar; 6(3): 189–201CrossRefGoogle Scholar
  32. 32.
    Spedding M, Jay T, Costa e Silva J, et al. A pathophysiological paradigm for the therapy of psychiatric disease. Nat Rev Drug Discov 2005 Jun; 4(6): 467–76PubMedCrossRefGoogle Scholar
  33. 33.
    Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001; 15(3): 231–59PubMedCrossRefGoogle Scholar
  34. 34.
    Chamba G, Lemoine P, Flachaire E, et al. Increased serotonin platelet uptake after tianeptine administration in depressed patients. Biol Psychiatry 1991 Sep 15; 30(6): 609–17PubMedCrossRefGoogle Scholar
  35. 35.
    Kato G, Weitsch AF. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol 1988; 11Suppl. 2: S43–50PubMedGoogle Scholar
  36. 36.
    Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol 2001 Apr; 16(3): 203–18PubMedCrossRefGoogle Scholar
  37. 37.
    Rajkowska G. Cell pathology in mood disorders. Semin Clin Neuropsychiatry 2002 Oct; 7(4): 281–92PubMedCrossRefGoogle Scholar
  38. 38.
    van der Flier WM, van Buchem MA, Weverling-Rijnsburger AW, et al. Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. J Neurol 2004 Jun; 251(6): 671–5PubMedCrossRefGoogle Scholar
  39. 39.
    von Gunten A, Ron MA. Hippocampal volume and subjective memory impairment in depressed patients. Eur Psychiatry 2004 Nov; 19(7): 438–40CrossRefGoogle Scholar
  40. 40.
    Vyas A, Mitra R, Shankaranarayana Rao BS, et al. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 2002 Aug 1; 22(15): 6810–8PubMedGoogle Scholar
  41. 41.
    Watanabe Y, Gould E, Daniels DC, et al. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 1992 Nov 3; 222(1): 157–62PubMedCrossRefGoogle Scholar
  42. 42.
    Lucassen PJ, Fuchs E, Czeh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004 Apr 15; 55(8): 789–96PubMedCrossRefGoogle Scholar
  43. 43.
    Plaisant F, Dommergues MA, Spedding M, et al. Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology 2003 May; 44(6): 801–9PubMedCrossRefGoogle Scholar
  44. 44.
    Alfonso J, Frick LR, Silberman DM, et al. Regulation of hippocampal gene expression is conserved in two species subjected to different Stressors and antidepressant treatments. Biol Psychiatry 2006 Feb 1; 59(3): 244–51PubMedCrossRefGoogle Scholar
  45. 45.
    Reagan LP, Hendry RM, Reznikov LR, et al. Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala. Eur J Pharmacol 2007 Jun 22; 565(1-3): 68–75PubMedCrossRefGoogle Scholar
  46. 46.
    Diamond DM, Campbell A, Park CR, et al. Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression. Eur Neuropsychopharmacol 2004 Dec; 14Suppl. 5: S491–5PubMedCrossRefGoogle Scholar
  47. 47.
    Rocher C, Spedding M, Munoz C, et al. Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. Cereb Cortex 2004 Feb; 14(2): 224–9PubMedCrossRefGoogle Scholar
  48. 48.
    Shakesby AC, Anwyl R, Rowan MJ. Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J Neurosci 2002 May 1; 22(9): 3638–44PubMedGoogle Scholar
  49. 49.
    Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sci 1990 May; 11(5): 205–11PubMedCrossRefGoogle Scholar
  50. 50.
    Erecinska M, Silver IA. Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 1990; 35(4): 245–96PubMedCrossRefGoogle Scholar
  51. 51.
    Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003 Nov; 1003: 250–72PubMedCrossRefGoogle Scholar
  52. 52.
    Zarate Jr CA, Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003 Nov; 1003: 273–91PubMedCrossRefGoogle Scholar
  53. 53.
    Lowy MT, Gault L, Yamamoto BK. Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. J Neurochem 1993 Nov; 61(5): 1957–60PubMedCrossRefGoogle Scholar
  54. 54.
    Lowy MT, Wittenberg L, Yamamoto BK. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995 Jul; 65(1): 268–74PubMedCrossRefGoogle Scholar
  55. 55.
    Reznikov LR, Grillo CA, Piroli GG, et al. Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci 2007 May; 25(10): 3109–14PubMedCrossRefGoogle Scholar
  56. 56.
    Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol 2001 Nov–Dec; 22(10): 1813–24PubMedGoogle Scholar
  57. 57.
    Magarinos AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement ofb glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 1995 Nov; 69(1): 89–98PubMedCrossRefGoogle Scholar
  58. 58.
    Auer DP, Putz B, Kraft E, et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000 Feb 15; 47(4): 305–13PubMedCrossRefGoogle Scholar
  59. 59.
    Kole MH, Swan L, Fuchs E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur J Neurosci. 2002 Sep; 16(5): 807–16PubMedCrossRefGoogle Scholar
  60. 60.
    Svenningsson P, Tzavara E, Nomikos G, et al. Biochemical modulation of AMPA receptor function by antidepressants [abstract no. S.04.02]. Eur Neuropsychopharmacol 2003; 13Suppl. 4: S102CrossRefGoogle Scholar
  61. 61.
    Reagan LP, Rosell DR, Wood GE, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc Natl Acad Sci U S A 2004 Feb 17; 101(7): 2179–84PubMedCrossRefGoogle Scholar
  62. 62.
    Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006 Mar; 27(3): 141–8PubMedCrossRefGoogle Scholar
  63. 63.
    Jaffard R, Mocaer E, Poignant JC, et al. Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice. Behav Pharmacol 1991 Feb; 2(1): 37–46PubMedCrossRefGoogle Scholar
  64. 64.
    Conrad CD, Galea LA, Kuroda Y, et al. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 1996 Dec; 110(6): 1321–34PubMedCrossRefGoogle Scholar
  65. 65.
    Campbell AM, Park CR, Zoladz PR, et al. Pre-training administrationof tianeptine, but not propranolol, protects hippocampus-dependent memory from being impaired by predator stress. Eur Neuropsychopharmacol. Epub 2007 Jun 11Google Scholar
  66. 66.
    Burghardt NS, Sullivan GM, McEwen BS, et al. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 2004 Jun 15; 55(12): 1171–8PubMedCrossRefGoogle Scholar
  67. 67.
    Novotný V, Faltus F. Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum Psychopharmacol 2002 Aug; 17(6): 299–303PubMedCrossRefGoogle Scholar
  68. 68.
    Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. CNS Drugs 2002; 16(1): 65–75PubMedCrossRefGoogle Scholar
  69. 69.
    Lepine JP, Altamura C, Ansseau M, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study. Hum Psychopharmacol 2001 Apr; 16(3): 219–27PubMedCrossRefGoogle Scholar
  70. 70.
    Costa e Silva JA, Ruschel SI, Caetano D, et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997; 35(1): 24–9PubMedCrossRefGoogle Scholar
  71. 71.
    Cassano GB, Heinze G, Lôo H, et al. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur Psychiatry 1996; 11(5): 254–9PubMedCrossRefGoogle Scholar
  72. 72.
    Dalery J, Dagens-Lafont V, De Bodinat C. Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression. Hum Psychopharmacol 2001 Jan; 16(S1): S39–47PubMedCrossRefGoogle Scholar
  73. 73.
    Guelfi JD, Pichot P, Dreyfus JF. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 1989; 22(1): 41–8PubMedCrossRefGoogle Scholar
  74. 74.
    Invernizzi G, Aguglia E, Bertolino A, et al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. Neuropsychobiology 1994; 30(2-3): 85–93PubMedCrossRefGoogle Scholar
  75. 75.
    Loo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1988; 19(2): 79–85PubMedCrossRefGoogle Scholar
  76. 76.
    Kamoun A, Delalleau B, Ozun M. Can a serotonin uptake agonist be an authentic antidepressant? Results of a multicenter, multinational therapeutic trial [in French]. Encephale 1994 Sep–Oct; 20(5): 521–5PubMedGoogle Scholar
  77. 77.
    Annseau M, Bataille M, Briole G, et al. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum Psychopharmacol 1996; 11: 293–8CrossRefGoogle Scholar
  78. 78.
    Brion S, Audrain S, de Bodinat C. Major depressive episodes in patients over 70 years of age: evaluation of the efficiency and acceptability of tianeptine and mianserin [in French]. Presse Med 1996 Mar 16; 25(9): 461–8PubMedGoogle Scholar
  79. 79.
    Alby JM, Ferreri M, Cabane J, et al. Efficacy of tianeptine (Stablon™) for the treatment of major depression and dysthymia with somatic complaints: a comparative study versus fluoxetine (Prozac™) [in French]. Ann Psychiatr 1993; 8(2): 136–44Google Scholar
  80. 80.
    Guelfi JD, Bouhassira M, Bonett-Perrin E, et al. The study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice [in French]. Encephale 1999 May–Jun; 25(3): 265–70PubMedGoogle Scholar
  81. 81.
    Loo H, Saiz-Ruiz J, Costa e Silva J, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 1999 Dec; 56(2-3): 109–18PubMedCrossRefGoogle Scholar
  82. 82.
    Novotný V, Faltus F. First signs of improvement with tianeptine in the treatment of depression: an analysis of a double-blind study versus fluoxetine [abstract P.1.132]. Eur Neuropsycho-pharmacol 2003; 13Suppl. 4: S230CrossRefGoogle Scholar
  83. 83.
    Kasper S, Olie JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 2002 Jul; 17Suppl. 3: 331–40PubMedCrossRefGoogle Scholar
  84. 84.
    Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19(2): 114–24PubMedGoogle Scholar
  85. 85.
    Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67(12): 1657–63PubMedCrossRefGoogle Scholar
  86. 86.
    Chapuy P, Cuny G, Delomier Y, et al. Depression in elderly patients. Value of tianeptine in 140 patients treated for 1 year [in French]. Presse Med 1991 Nov 14; 20(37): 1844-52PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of Psychiatry and PsychotherapyMedical University of ViennaViennaAustria
  2. 2.The Rockefeller UniversityNew YorkUSA

Personalised recommendations